Amylyx Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary

Amylyx Pharmaceuticals

06/08/2026 14:02

Amylyx Pharmaceuticals, Inc. AMLX.OQ reported a quarterly adjusted loss of 39 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -46 cents.  The mean expectation of nine analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -41 cents to -33 cents per share.
Reported revenue was zero​; analysts expected zero. 
Amylyx Pharmaceuticals, Inc.'s reported EPS for the quarter was a loss of 39 cents​.
The company reported a quarterly loss of $43.42 million.
Amylyx Pharmaceuticals, Inc. shares had risen by 21.7% this quarter and gained 80.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Amylyx Pharmaceuticals, Inc. is $24.00, about 9% above its last closing price of $21.85
This summary was machine generated from LSEG data August 6 at 01:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.36
-0.39
Missed
Mar. 31 2026 
-0.33
-0.37
Missed
Dec. 31 2025 
-0.36
-0.30
Beat
Sep. 30 2025 
-0.45
-0.37
Beat